Hemogenyx Pharmaceuticals PLC Result of Annual General Meeting
28 June 2024 - 1:39AM
RNS Regulatory News
RNS Number : 2254U
Hemogenyx Pharmaceuticals PLC
27 June 2024
27 June 2024
Hemogenyx Pharmaceuticals
plc
("Hemogenyx
Pharmaceuticals" or the "Company")
Result of Annual General
Meeting
Hemogenyx Pharmaceuticals plc is pleased to
announce that, at the Annual General Meeting ("AGM") held earlier
today, all resolutions were duly passed on a show of hands. The
numbers of proxy votes for each resolution submitted prior to the
meeting are presented below.
Proxy Voting
Results
|
Ordinary Resolutions
|
Votes for
|
% of
votes cast for
|
Votes Against
|
% of
votes cast against
|
Total votes cast
|
Total votes cast as % of ISC (1)
|
Votes with-held (2)
|
|
1. To receive and adopt the Company's
annual accounts for the year ended 31 December 2023.
|
172,981,350
|
99.89
|
189,346
|
0.11
|
173,170,696
|
12.91
|
804,255
|
|
2. To approve the Directors'
Remuneration Report which is set out in the 2023 Annual Report and
Accounts.
|
155,914,909
|
90.14
|
17,056,623
|
9.86
|
172,971,532
|
12.89
|
1,003,419
|
|
3. To re-appoint Sir Marc Feldmann as
a Director of the Company.
|
168,819,296
|
97.51
|
4,316,573
|
2.49
|
173,135,869
|
12.90
|
839,082
|
|
4. To re-appoint PKF Littlejohn LLP
as auditor of the Company to hold office until the conclusion of
the next Annual General Meeting of the Company.
|
156,805,252
|
99.10
|
1,429,684
|
0.90
|
158,234,936
|
11.79
|
15,740,015
|
|
5. To authorise the Audit Committee
to agree the auditor's remuneration.
|
157,329,629
|
90.99
|
15,576,903
|
9.01
|
172,906,532
|
12.89
|
1,068,419
|
|
6. To authorise the Directors to
allot shares pursuant to section 551 of the Companies Act
2006.
|
153,328,931
|
88.71
|
19,513,766
|
11.29
|
172,842,697
|
12.88
|
1,132,254
|
|
Special Resolutions
|
Votes for
|
% of
votes cast for
|
Votes against
|
% of
votes cast against
|
Total votes cast
|
Total votes cast as % of ISC (1)
|
Votes with-held (2)
|
|
7. To disapply pre-emption rights
under section 570 of the Companies Act 2006.
|
152,661,902
|
88.30
|
20,235,808
|
11.70
|
172,897,710
|
12.89
|
1,077,241
|
|
8. To approve
for calling of general meetings (other than AGMs) on 14 days'
notice.
|
172,081,747
|
99.38
|
1,080,015
|
0.62
|
173,161,762
|
12.91
|
813,189
|
(1) The
Company's issued share capital ("ISC") on 25 June
2024, being the date on which members had to be entered in the
register of members of the Company in order to be entitled to
attend and vote at the meeting, was 1,341,815,988 ordinary
shares.
(2) A
'vote withheld' in respect of any resolution is not a vote in law
and is not counted in the calculation of the proportion of the
votes for and against it.
A copy of the resolutions passed has been
submitted to the National Storage Mechanism and will shortly be
available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Enquiries:
|
Hemogenyx Pharmaceuticals plc
|
https://hemogenyx.com
|
|
Dr Vladislav Sandler, Chief
Executive Officer & Co-Founder
|
headquarters@hemogenyx.com
|
|
Peter Redmond, Director
|
peter.redmond@hemogenyx.com
|
|
|
|
|
SP
Angel Corporate Finance LLP
|
Tel: +44 (0)20 3470 0470
|
|
Matthew Johnson, Vadim Alexandre,
Adam Cowl
|
|
|
|
|
|
Peterhouse Capital Limited
|
Tel: +44 (0)20 7469 0930
|
|
Lucy Williams, Duncan Vasey, Charles
Goodfellow
|
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
RAGQKOBNPBKDOAB
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From May 2024 to Jul 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Jul 2023 to Jul 2024
